Patents by Inventor Cornelia Anne Mundt

Cornelia Anne Mundt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210023214
    Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 28, 2021
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
  • Anti-LAG-3 antibodies and methods of use thereof
    Patent number: 10882908
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: January 5, 2021
    Assignee: Agenus Inc.
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • Anti-LAG-3 antibodies and methods of use thereof
    Patent number: 10844119
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: November 24, 2020
    Assignee: AGENUS INC.
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200362037
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: August 10, 2020
    Publication date: November 19, 2020
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200354455
    Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: April 24, 2020
    Publication date: November 12, 2020
    Inventors: Marc VAN DIJK, Cornelia Anne MUNDT, Gerd RITTER, David SCHAER, Jedd David WOLCHOK, Taha MERGHOUB, David Adam SAVITSKY, Nicholas Stuart WILSON
  • ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200354454
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: April 24, 2020
    Publication date: November 12, 2020
    Inventors: Marc VAN DIJK, Cornelia Anne MUNDT, Gerd RITTER, Jedd David WOLCHOK, Taha MERGHOUB, Roberta ZAPPASODI, Rikke Bæk HOLMGAARD, David SCHAER, David Adam SAVITSKY, Nicholas Stuart WILSON
  • T CELL RECEPTORS THAT BIND TO NY-ESO-1 AND METHODS OF USE THEREOF
    Publication number: 20200040358
    Abstract: Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
    Type: Application
    Filed: July 15, 2019
    Publication date: February 6, 2020
    Inventors: Marc Van Dijk, Volker Seibert, Cornelia Anne Mundt, Arthur Andrew Hurwitz, Mark Adrian Exley, Benjamin Jacob Wolf, Daniel Leventhal, Sébastien Lalevée, Reed Masakayan
  • ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200024350
    Abstract: Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies either alone or in combination.
    Type: Application
    Filed: June 7, 2019
    Publication date: January 23, 2020
    Inventors: Marc VAN DIJK, Cornelia Anne MUNDT, Gerd RITTER, David SCHAER, Jedd David WOLCHOK, Taha MERGHOUB, Nicholas Stuart WILSON, David Adam SAVITSKY, Mark Arthur FINDEIS, Roberta ZAPPASODI, Rikke Bæk HOLMGAARD, Jean-Marie CUILLEROT, Igor PROSCURSHIM, Olga SHEBANOVA
  • Anti-CTLA-4 antibodies and methods of use thereof
    Patent number: 10479833
    Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: November 19, 2019
    Assignees: AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson
  • Anti-PD-1 antibodies and methods of use thereof
    Patent number: 10450373
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: October 22, 2019
    Assignees: AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Baek Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson
  • ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190256601
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 22, 2019
    Inventors: MARC VAN DIJK, CORNELIA ANNE MUNDT, GERD RITTER, JEDD DAVID WOLCHOK, TAHA MERGHOUB, ROBERTA ZAPPASODI, RIKKE BAEK HOLMGAARD, DAVID SCHAER, DAVID ADAM SAVITSKY, NICHOLAS STUART WILSON
  • Anti-PD-1 antibodies and methods of use thereof
    Patent number: 10323091
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 18, 2019
    Assignees: Agenus Inc., Memorial Sloan Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd
    Inventors: Marc van Dijk, Nicholas Stuart Wilson, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky
  • ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190135919
    Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: October 19, 2018
    Publication date: May 9, 2019
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson
  • ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180344870
    Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: April 12, 2018
    Publication date: December 6, 2018
    Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk
  • Anti-CTLA-4 antibodies and methods of use thereof
    Patent number: 10144779
    Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: December 4, 2018
    Assignees: AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson
  • ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180185481
    Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: December 7, 2017
    Publication date: July 5, 2018
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
  • ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20180127499
    Abstract: The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: October 11, 2017
    Publication date: May 10, 2018
    Inventors: Nicholas Stuart Wilson, David Adam Savitsky, Shawn Michael Jennings, Marc van Dijk, Cornelia Anne Mundt
  • ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20170081409
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 23, 2017
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson
  • ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20160368989
    Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 22, 2016
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Mark Arthur Findeis, Nicholas Stuart Wilson